Development and validation of a composite programmatic assessment tool for HIV therapy

Area of Science:

• Infectious Diseases
• Public Health
• Clinical Medicine

Background:

• Developed and validated the Programmatic Compliance Score (PCS), a novel metric based on IAS-USA antiretroviral therapy guidelines for HIV-infected adults.
• Hypothesized that non-compliance with guidelines, as measured by PCS, would predict all-cause mortality at a program level.

Purpose of the Study:

• To assess the Programmatic Compliance Score (PCS) as a predictor of all-cause mortality in HIV-infected adults initiating antiretroviral therapy (ART).
• To validate the IAS-USA treatment guidelines through an independent metric.

Main Methods:

• Retrospective cohort study of 3543 ART-naive HIV-infected patients in British Columbia, Canada (2000-2010).
• PCS developed using six indicators: CD4/viral load testing frequency, resistance testing, regimen appropriateness, baseline CD4 count, and viral suppression achievement.
• All-cause mortality as the primary outcome, analyzed in relation to PCS score.

Main Results:

• Each PCS component was independently associated with increased mortality risk.
• Patients with a PCS score of ≥4 had a significantly higher odds ratio (22.37) for all-cause mortality compared to those with a score of 0.
• The PCS demonstrated a strong association with all-cause mortality.

Conclusions:

• The Programmatic Compliance Score (PCS) is a strong predictor of all-cause mortality in HIV-infected adults on ART.
• Findings independently validate the IAS-USA antiretroviral therapy management guidelines.
• Further development and targeted interventions using PCS are recommended to improve clinical outcomes for HIV patients.